{"name":"Appello Pharmaceuticals, Inc.","slug":"appello-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AP-472","genericName":"AP-472","slug":"ap-472","indication":"Treatment-resistant depression","status":"phase_2"}]}],"pipeline":[{"name":"AP-472","genericName":"AP-472","slug":"ap-472","phase":"phase_2","mechanism":"AP-472 is a small molecule that targets the serotonin receptor 5-HT2A.","indications":["Treatment-resistant depression"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNQXJsOGYwN0psa0MyWjd2OG9ac2lhcjhBajZBc1I0bzFkYmR3XzNKT2FPWTN0MmJTQkVhc3RPejBwZ2t1MXc1OXFvc2hfczhVc0pScFd4R21XTmY1SlFxeXB3dDJJM01CVVNPNTJXVDF0ZE4zNVhtTFpQY094aVlyN0h6eFlMM09uWDd2TEN3NTI0Q0U?oc=5","date":"2022-11-10","type":"pipeline","source":"BioSpace","summary":"Parkinson’s Disease Treatment Market Size, Share | Report 2022-2030 - BioSpace","headline":"Parkinson’s Disease Treatment Market Size, Share | Report 2022-2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQMGdJNXE1cXY5QmNpaWFIZkxIQUw0cGdKSnN4SFhBejI0ZFVwcGRGV2x4ejZDN3FHYnljS0dZdllHZFg1R203QnMzbnZfQm1UYnUyVjZ0V3ZrMk1uaFVSSFVzUHNmck5TUWl0QjlQMmU0bE1SaTd1cEdSeTVoQmxyak1oYWhBNjYydW81ZDRXbHZCRHNDZm8zckt0TEVtREhwdUZSYlg1aE9ia18zNWtpSEJHMDloOW1JcmRnSg?oc=5","date":"2022-10-31","type":"pipeline","source":"The Business Journals","summary":"Cass Pharmaceuticals raises nearly $2 million - The Business Journals","headline":"Cass Pharmaceuticals raises nearly $2 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOVWZsUEp5cEI4N0Q4RFhiajJBakJudExsb0xEN0J6dkZULU5zZE5uREFRdWo4TUdsa1E2ZU5rNnIzY1pmRjBFb3RsRzcydGVPZUpQT1BCUzV4eHlrWEgxTmUzMEVpUW9HZUJQOVlCQ0pxcVpCRHZxRmpZNlp4a2p2cmppZ2s0MkJOdFEtY01KbzRvdVgwZWJscmZseXo3YkV6cWc?oc=5","date":"2021-10-07","type":"trial","source":"Parkinson's News Today","summary":"Dosing Begins in Phase 1 Trial of AP-472, for Dyskinesia With Levodopa - Parkinson's News Today","headline":"Dosing Begins in Phase 1 Trial of AP-472, for Dyskinesia With Levodopa - Parkinson's News Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxObXd1WjA2czE0a3JKblRFb29nV0g5Q0xrUERQS1FPMzRvRnY5QmpmMFc4LWxGRXVDRkpZdWxKSkIxLVViQzA1aEpmTnhNY1psbVlHZVZJYlFrZVl2WjQ1cWhJZnNESXRjLW5IcEcxOXFhT2FqdVJpNmhVZWJpU2dRZGtJakRxQmRYRkQ5VHlvdWZQUXFkbWRMZ2R5MmZWMy0xdUtqS1ZvVXR1d3EtTVE?oc=5","date":"2021-10-04","type":"trial","source":"PR Newswire","summary":"Appello Pharmaceuticals Begins Phase 1 Clinical Trial - PR Newswire","headline":"Appello Pharmaceuticals Begins Phase 1 Clinical Trial","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}